In vivo expression of soluble Fas and FAP-1: Possible mechanisms of Fas resistance in human hepatoblastomas

Journal of Pathology

Volumn 188, Issue 2, 1999, Pages 207-212

  Lee, Sug H ^a   Shin, Min S ^a   Lee, Jung Y ^a   Park, Won S ^a   Kim, Su Y ^a   Jang, Ja J ^b   Dong, Seung M ^a   Na, Eun Y ^a   Kim, Choo S ^a   Kim, Sang H ^a   Yoo, Nam J ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Apoptosis; Hepatoblastoma; In situ reverse transcription polymerase chain reaction; Soluble Fas

Indexed keywords

FAS ANTIGEN; PHOSPHATASE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD95; APOPTOSIS; CARRIER PROTEINS; CYTOPLASM; FAS LIGAND PROTEIN; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0033054108     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199906)188:2<207::AID-PATH337>3.0.CO;2-8     Document Type: Article

References (34)

1. Raney B. Hepatoblastoma in children: a review. J Pediatr Hematol Oncol 1997; 19: 418-422.
2. Raff MC. Social controls on cell survival and cell death. Nature 1992; 356: 397-400.
3. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
4. Trauth BC, Klas C, Peters AMJ, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
5. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747-1756.
6. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-243.
7. Ogasawara J, Watanabe FR, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
8. Leithäuser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the new grow factor/tumor necrosis receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-429.
9. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
10. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas of nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responses. Cancer Res 1994; 54: 1580-1586.
11. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-1178.
12. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counter-attack: Fas-mediated T cell killing by colon cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
13. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
14. Martin SJ, Green DR. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 1991; 18: 137-153.
15. Sato T, Irie S, Kituda S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411-415.
16. Mori S, Murakami-Mori K, Jewett A, Nakamura S, Bonavida B. Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Cancer Res 1996; 56: 1874-1879.
17. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195.
18. Landowsky TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90: 4266-4270.
19. Tamiya S, Etoh KI, Suzushima H, Takatsuki K, Matsuoka M. Mutation of CD95 (Fas/APO-1) gene in adult T-cell leukemia cells. Blood 1998; 91: 3935-3942.
20. Beltinger C, Kurz E, Bohler T, Schrappe M, Ludwig WD, Debatin KM. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91: 3943-3951.
21. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997; 94: 13862-13867.
22. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression on Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
23. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-1012.
24. Natoli G, Ianni A, Costanzo A, et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995; 11: 1157-1164.
25. Rieux-Laucat F, Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-1349.
26. Ishak KG, Glunz PR. Hepatoblastoma and hepatocellular carcinoma in infancy and childhood: report of 47 cases. Cancer 1997; 20: 396-422.
27. Lee SH, Kim SY, Lee JY, et al. Detection of soluble Fas using in situ reverse transcription-polymerase chain reaction. Lab Invest 1998; 78: 453-459.
28. Peters J, Krams M, Wacker HH, et al. Detection of rare RNA sequences by single-enzyme in situ reverse transcription-polymerase chain reaction. Am J Pathol 1997; 150: 469-476.
29. Dong SM, Kim KM, Kim SY, et al. Frequent somatic mutations in serinelthreonine kinase 11/Peutz-Jeghers syndrome gene in left-sided colon cancer. Cancer Res 1998; 58: 3787-3790.
30. Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403-413.
31. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T-cell survival by enhancing the expression of Bcl-xL. Immunity 1995; 3: 87-98.
32. O'Leary JJ, Chetty R, Graham AK, McGee JO. In situ PCR: pathologist's dream or nightmare? J Pathol 1996; 178: 11-20.
33. Yoshihiro N, Hughes SJ, Rehemtula A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adeno carcinomas. J Clin Invest 1998; 101: 1102-1110.
34. Hughes SJ, Nambu Y, Soldes OS, et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinomas. Cancer Res 1997; 57: 5571-5578.